Announcement • May 22
Givaudan SA, Annual General Meeting, Mar 24, 2027 Givaudan SA, Annual General Meeting, Mar 24, 2027. Announcement • Apr 15
Givaudan SA to Report Fiscal Year 2026 Results on Jan 27, 2027 Givaudan SA announced that they will report fiscal year 2026 results on Jan 27, 2027 Announcement • Apr 08
Givaudan Active Beauty Showcases AI-Powered Ingredient Innovations With Haut.AI At In-Cosmetics Global Givaudan Active Beauty, the reference in high-precision beauty ingredients, has partnered with Haut.AI, to spotlight a new era of AI-driven ingredient innovation. At this year's in-cosmetics Global 2026 (April 14–16, Paris), Givaudan Active Beauty will be the first to showcase its latest active ingredients through immersive GenAI-powered activations that allow attendees to virtually "experience" their benefits firsthand via personalized, photorealistic simulations powered by Haut.AI's SkinGPT technology. As the beauty industry accelerates toward measurable efficacy, personalization, and clinically validated claims, artificial intelligence is becoming a critical bridge between laboratory science and visible consumer outcomes. In this spirit, Givaudan has selected Haut.AI's scientifically grounded skin analysis and SkinGPT simulation technologies to deliver an interactive, ingredient-focused experience at one of the industry's most influential global stages. Building on this collaboration, Givaudan Active Beauty's latest active ingredient will serve as the foundation for an interactive SkinGPT-powered virtual try-on experience at the Givaudan booth in Paris. By taking a selfie of their own face, attendees will be able to digitally "apply" the ingredient and visualize how it may influence visible skin parameters over time through a photorealistic simulation. Meanwhile they will be able to experience an AI Skin Expert analyzing their skin and delivering personalized recommendations of high precision beauty ingredients. Givaudan Active Beauty's latest breakthrough, PrimalHyal™ NeuroYouth targets the newly identified Neuro Skin Ageing pathway, supporting nerve fiber regeneration and neuronal function. By integrating AI-powered validation and immersive simulations at booth at in-cosmetics Global, the company will share this innovation in a way that allows both customers and consumers to truly experience it. Visitors to the Givaudan Active Beauty booth will be invited to engage with two AI-powered experiences: SkinGPT: At in-cosmetics Global 2026, Givaudan will unveil its latest active ingredient in an immersive experience. For the first time, attendees will be able to literally try on the formulation on their own skin through a live facial scan, instantly visualizing how it may transform visible skin parameters over time. AI Skin Expert: An on-site skin assessment providing participants with comprehensive skin insights and active ingredient recommendations aligned with their unique skin characteristics. Upcoming Dividend • Mar 16
Upcoming dividend of CHF72.00 per share Eligible shareholders must have bought the stock before 23 March 2026. Payment date: 25 March 2026. Payout ratio is a comfortable 62% and this is well supported by cash flows. Trailing yield: 2.6%. Lower than top quartile of British dividend payers (5.7%). Lower than average of industry peers (4.1%). Announcement • Feb 23
Givaudan SA, Annual General Meeting, Mar 19, 2026 Givaudan SA, Annual General Meeting, Mar 19, 2026, at 10:30 W. Europe Standard Time. Declared Dividend • Feb 01
Dividend increased to CHF72.00 Dividend of CHF72.00 is 2.9% higher than last year. Ex-date: 23rd March 2026 Payment date: 25th March 2026 Dividend yield will be 2.4%, which is lower than the industry average of 3.0%. Sustainability & Growth Dividend is covered by both earnings (62% earnings payout ratio) and cash flows (55% cash payout ratio). The dividend has increased by an average of 2.9% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 18% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Reported Earnings • Jan 30
Full year 2025 earnings released: EPS: CHF116 (vs CHF118 in FY 2024) Full year 2025 results: EPS: CHF116 (down from CHF118 in FY 2024). Revenue: CHF7.47b (flat on FY 2024). Net income: CHF1.07b (down 1.7% from FY 2024). Profit margin: 14% (in line with FY 2024). Revenue is forecast to grow 4.6% p.a. on average during the next 3 years, compared to a 15% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings. Announcement • Jan 30
Givaudan SA announces Annual dividend, payable on March 25, 2026 Givaudan SA announced Annual dividend of CHF 72.0000 per share payable on March 25, 2026, ex-date on March 23, 2026 and record date on March 24, 2026. Announcement • Nov 08
Givaudan SA to Report First Half, 2026 Results on Jul 23, 2026 Givaudan SA announced that they will report first half, 2026 results on Jul 23, 2026 Announcement • Aug 28
Givaudan SA Announces CEO Changes Givaudan SA announced that Christian Stammkoetter would succeed its Chief Executive Officer, Gilles Andrier, who will retire after 20 years at the helm of the company. Stammkoetter-- who is currently president of Asia, Middle East and Africa at the French food company Danone--would take over the role effective March 1. Andrier will be proposed for election as chairman at the 2026 annual general meeting as Calvin Grieder is set to step down from the board after 12 years. Reported Earnings • Jul 24
First half 2025 earnings released: EPS: CHF64.18 (vs CHF63.76 in 1H 2024) First half 2025 results: EPS: CHF64.18 (up from CHF63.76 in 1H 2024). Revenue: CHF3.86b (up 3.4% from 1H 2024). Net income: CHF592.0m (flat on 1H 2024). Profit margin: 15% (in line with 1H 2024). Revenue is forecast to grow 4.6% p.a. on average during the next 3 years, compared to a 15% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth. Announcement • Apr 10
Givaudan SA to Report Fiscal Year 2025 Results on Jan 29, 2026 Givaudan SA announced that they will report fiscal year 2025 results on Jan 29, 2026 Upcoming Dividend • Mar 17
Upcoming dividend of CHF70.00 per share Eligible shareholders must have bought the stock before 24 March 2025. Payment date: 26 March 2025. Payout ratio is a comfortable 59% and this is well supported by cash flows. Trailing yield: 1.8%. Lower than top quartile of British dividend payers (6.1%). Lower than average of industry peers (4.2%). Announcement • Feb 24
Givaudan SA, Annual General Meeting, Mar 20, 2025 Givaudan SA, Annual General Meeting, Mar 20, 2025, at 10:30 W. Europe Standard Time. Declared Dividend • Feb 17
Dividend increased to CHF70.00 Dividend of CHF70.00 is 2.9% higher than last year. Ex-date: 24th March 2025 Payment date: 26th March 2025 Dividend yield will be 1.7%, which is lower than the industry average of 3.0%. Sustainability & Growth Dividend is covered by both earnings (59% earnings payout ratio) and cash flows (48% cash payout ratio). The dividend has increased by an average of 3.4% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 21% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Reported Earnings • Jan 25
Full year 2024 earnings released: EPS: CHF118 (vs CHF96.81 in FY 2023) Full year 2024 results: EPS: CHF118 (up from CHF96.81 in FY 2023). Revenue: CHF7.41b (up 7.2% from FY 2023). Net income: CHF1.09b (up 22% from FY 2023). Profit margin: 15% (up from 13% in FY 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 4.8% p.a. on average during the next 3 years, compared to a 3.4% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Announcement • Aug 24
Givaudan SA to Report Q3, 2025 Results on Oct 14, 2025 Givaudan SA announced that they will report Q3, 2025 results at 7:00 AM, Central European Standard Time on Oct 14, 2025 Announcement • Aug 23
Givaudan SA to Report First Half, 2025 Results on Jul 22, 2025 Givaudan SA announced that they will report first half, 2025 results on Jul 22, 2025 Reported Earnings • Jul 24
First half 2024 earnings released: EPS: CHF63.76 (vs CHF48.69 in 1H 2023) First half 2024 results: EPS: CHF63.76 (up from CHF48.69 in 1H 2023). Revenue: CHF3.74b (up 5.7% from 1H 2023). Net income: CHF588.0m (up 31% from 1H 2023). Profit margin: 16% (up from 13% in 1H 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 5.1% p.a. on average during the next 3 years, compared to a 6.8% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. Announcement • Jul 02
Givaudan SA (SWX:GIVN) acquired remaining 75% stake in B. Kolormakeup & Skincare S.p.a. Givaudan SA (SWX:GIVN) acquired remaining 75% stake in B. Kolormakeup & Skincare S.p.a. on July 1, 2024. Givaudan plans to finance this acquisition through debt.Givaudan SA (SWX:GIVN) completed the acquisition of remaining 75% stake in B. Kolormakeup & Skincare S.p.a. Buy Or Sell Opportunity • Jul 01
Now 16% overvalued after recent price rise Over the last 90 days, the stock has risen 7.1% to CHF4,302. The fair value is estimated to be CHF3,712, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 3.6% over the last 3 years. Earnings per share has grown by 4.9%. For the next 3 years, revenue is forecast to grow by 4.8% per annum. Earnings are also forecast to grow by 7.8% per annum over the same time period. Buy Or Sell Opportunity • Jun 21
Now 21% overvalued after recent price rise Over the last 90 days, the stock has risen 6.7% to CHF4,322. The fair value is estimated to be CHF3,564, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 3.6% over the last 3 years. Earnings per share has grown by 4.9%. For the next 3 years, revenue is forecast to grow by 4.8% per annum. Earnings are also forecast to grow by 7.8% per annum over the same time period. Announcement • Apr 12
Givaudan SA to Report Fiscal Year 2024 Results on Jan 24, 2025 Givaudan SA announced that they will report fiscal year 2024 results on Jan 24, 2025 Upcoming Dividend • Mar 18
Upcoming dividend of CHF68.00 per share Eligible shareholders must have bought the stock before 25 March 2024. Payment date: 27 March 2024. Payout ratio is a comfortable 70% and this is well supported by cash flows. Trailing yield: 1.7%. Lower than top quartile of British dividend payers (6.2%). Lower than average of industry peers (3.0%). Announcement • Feb 08
Groupe Berkem Société anonyme (ENXTPA:ALKEM) signed a definitive agreement to acquire Naturex Iberian Partners, S.L.U from Givaudan SA (SWX:GIVN) . Groupe Berkem Société anonyme (ENXTPA:ALKEM) signed a definitive agreement to acquire Naturex Iberian Partners, S.L.U from Givaudan SA (SWX:GIVN) on February 6, 2024. The acquisition will be 100% funded by the External Growth Credit Line contracted by Groupe Berkem. The transaction is expected to be closed on May 31, 2024. Oghma Partners acted as exclusive corporate finance advisor to Givaudan S.A. Declared Dividend • Jan 28
Dividend increased to CHF68.00 Dividend of CHF68.00 is 1.5% higher than last year. Ex-date: 25th March 2024 Payment date: 27th March 2024 Dividend yield will be 1.9%, which is lower than the industry average of 3.0%. Sustainability & Growth Dividend is covered by both earnings (70% earnings payout ratio) and cash flows (69% cash payout ratio). The dividend has increased by an average of 6.6% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 23% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Reported Earnings • Jan 26
Full year 2023 earnings released: EPS: CHF96.81 (vs CHF92.83 in FY 2022) Full year 2023 results: EPS: CHF96.81 (up from CHF92.83 in FY 2022). Revenue: CHF6.92b (down 2.8% from FY 2022). Net income: CHF893.0m (up 4.3% from FY 2022). Profit margin: 13% (in line with FY 2022). Revenue is forecast to grow 4.3% p.a. on average during the next 3 years, compared to a 4.6% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. Announcement • Oct 19
Givaudan SA to Report First Half, 2024 Results on Jul 23, 2024 Givaudan SA announced that they will report first half, 2024 results on Jul 23, 2024 Announcement • Oct 17
Givaudan SA, Annual General Meeting, Mar 21, 2024 Givaudan SA, Annual General Meeting, Mar 21, 2024. Reported Earnings • Jul 21
First half 2023 earnings released: EPS: CHF48.69 (vs CHF47.74 in 1H 2022) First half 2023 results: EPS: CHF48.69 (up from CHF47.74 in 1H 2022). Revenue: CHF3.54b (down 3.2% from 1H 2022). Net income: CHF449.0m (up 2.0% from 1H 2022). Profit margin: 13% (in line with 1H 2022). Revenue is forecast to grow 4.8% p.a. on average during the next 3 years, compared to a 7.4% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings. Upcoming Dividend • Mar 20
Upcoming dividend of CHF67.00 per share at 2.3% yield Eligible shareholders must have bought the stock before 27 March 2023. Payment date: 29 March 2023. Payout ratio is a comfortable 72% and the cash payout ratio is 94%. Trailing yield: 2.3%. Lower than top quartile of British dividend payers (5.7%). Lower than average of industry peers (3.1%). Upcoming Dividend • Mar 20
Upcoming dividend of CHF67.00 per share at 2.3% yield Eligible shareholders must have bought the stock before 27 March 2023. Payment date: 29 March 2023. Payout ratio is a comfortable 72% and the cash payout ratio is 94%. Trailing yield: 2.3%. Lower than top quartile of British dividend payers (5.7%). Lower than average of industry peers (3.1%). Reported Earnings • Jan 26
Full year 2022 earnings released: EPS: CHF92.83 (vs CHF89.03 in FY 2021) Full year 2022 results: EPS: CHF92.83 (up from CHF89.03 in FY 2021). Revenue: CHF7.12b (up 6.5% from FY 2021). Net income: CHF856.0m (up 4.3% from FY 2021). Profit margin: 12% (in line with FY 2021). Revenue is forecast to grow 4.8% p.a. on average during the next 3 years, compared to a 1.9% growth forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. Announcement • Jan 25
Givaudan SA to Report Fiscal Year 2023 Results on Jan 25, 2024 Givaudan SA announced that they will report fiscal year 2023 results on Jan 25, 2024 Announcement • Oct 12
Givaudan SA to Report Q2, 2022 Results on Jul 20, 2023 Givaudan SA announced that they will report Q2, 2022 results at 7:00 AM, Central European Standard Time on Jul 20, 2023 Reported Earnings • Jul 22
First half 2022 earnings released First half 2022 results: Revenue: (down 100% from 1H 2021). Net income: (down CHF481.0m from profit in 1H 2021). Profit margin: (down from 14% in 1H 2021). The decrease in margin was driven by lower expenses. Over the next year, revenue is forecast to grow 5.8% compared to a 15% decline forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 6% per year whereas the company’s share price has increased by 8% per year. Announcement • Jul 22
Givaudan SA to Report Fiscal Year 2022 Results on Jan 25, 2023 Givaudan SA announced that they will report fiscal year 2022 results on Jan 25, 2023 Upcoming Dividend • Mar 21
Upcoming dividend of CHF66.00 per share Eligible shareholders must have bought the stock before 28 March 2022. Payment date: 30 March 2022. Payout ratio is a comfortable 74% and this is well supported by cash flows. Trailing yield: 1.7%. Lower than top quartile of British dividend payers (4.6%). Lower than average of industry peers (2.6%). Announcement • Feb 16
Givaudan SA, Annual General Meeting, Mar 23, 2023 Givaudan SA, Annual General Meeting, Mar 23, 2023. Reported Earnings • Jan 30
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Full year 2021 results: EPS: CHF89.03 (up from CHF80.59 in FY 2020). Revenue: CHF6.68b (up 5.7% from FY 2020). Net income: CHF821.0m (up 11% from FY 2020). Profit margin: 12% (in line with FY 2020). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 6.4% compared to a 3.5% decline forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has increased by 17% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Jan 30
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Full year 2021 results: EPS: CHF89.03 (up from CHF80.59 in FY 2020). Revenue: CHF6.68b (up 5.7% from FY 2020). Net income: CHF821.0m (up 11% from FY 2020). Profit margin: 12% (in line with FY 2020). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 6.4% compared to a 3.5% decline forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has increased by 17% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Jul 24
First half 2021 earnings released: EPS CHF52.19 (vs CHF44.81 in 1H 2020) The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: CHF3.37b (up 4.7% from 1H 2020). Net income: CHF481.0m (up 17% from 1H 2020). Profit margin: 14% (up from 13% in 1H 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has increased by 25% per year, which means it is tracking significantly ahead of earnings growth. Upcoming Dividend • Mar 22
Upcoming Dividend of CHF64.00 Per Share Will be paid on the 31st of March to those who are registered shareholders by the 29th of March. The trailing yield of 1.8% is below the top quartile of British dividend payers (4.4%), but is in line with industry peers (1.7%). Is New 90 Day High Low • Feb 23
New 90-day low: CHF3,511 The company is down 2.0% from its price of CHF3,585 on 25 November 2020. The British market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 18% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CHF2,220 per share. Valuation Update With 7 Day Price Move • Feb 05
Investor sentiment deteriorated over the past week After last week's 20% share price decline to CHF2,995, the stock is trading at a trailing P/E ratio of 44.3x, down from the previous P/E ratio of 55.1x. This compares to an average P/E of 41x in the Chemicals industry in the United Kingdom. Total returns to shareholders over the past three years are 53%. Is New 90 Day High Low • Feb 05
New 90-day low: CHF2,995 The company is down 24% from its price of CHF3,930 on 06 November 2020. The British market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 16% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CHF1,872 per share. Analyst Estimate Surprise Post Earnings • Feb 03
Revenue misses expectations Revenue missed analyst estimates by 1.1%. Over the next year, revenue is forecast to grow 3.6% compared to a 11% decline forecast for the Chemicals industry in the United Kingdom. Analyst Estimate Surprise Post Earnings • Feb 02
Revenue misses expectations Revenue missed analyst estimates by 1.1%. Over the next year, revenue is forecast to grow 4.3% compared to a 11% decline forecast for the Chemicals industry in the United Kingdom. Analyst Estimate Surprise Post Earnings • Jan 31
Revenue misses expectations Revenue missed analyst estimates by 1.1%. Over the next year, revenue is forecast to grow 5.8% compared to a 11% decline forecast for the Chemicals industry in the United Kingdom. Reported Earnings • Jan 30
Full year 2020 earnings released: EPS CHF80.59 (vs CHF76.17 in FY 2019) The company reported a solid full year result with improved earnings and revenues, although profit margins were flat. Full year 2020 results: Revenue: CHF6.32b (up 1.9% from FY 2019). Net income: CHF743.0m (up 5.8% from FY 2019). Profit margin: 12% (in line with FY 2019). Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has increased by 19% per year, which means it is tracking significantly ahead of earnings growth. Is New 90 Day High Low • Dec 04
New 90-day low: CHF3,551 The company is down 7.0% from its price of CHF3,810 on 04 September 2020. The British market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CHF1,941 per share. Is New 90 Day High Low • Nov 11
New 90-day low: CHF3,672 The company is down 4.0% from its price of CHF3,813 on 13 August 2020. The British market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CHF2,050 per share. Is New 90 Day High Low • Oct 05
New 90-day high: CHF4,078 The company is up 15% from its price of CHF3,541 on 07 July 2020. The British market is down 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CHF1,996 per share.